Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Beholder  – Russia, 2019-11-19 15:39 (1172 d 02:51 ago) – Posting: # 20828
Views: 4,371

❝ We don't know nothing about new FDC - no safety, no efficacy data. This is new drug.


Why no safety and efficacy data!? Lets take abovementioned examples:

Amlodipine + Indapamide + Perindopril - here
Losartan + Amlodipine + Rosuvastatin - here.
Indapamide + Rosuvastatin + Perindopril here.

So, can we say that "In all cases, the established regime has a well-characterized safety and efficacy profile..." and proceed with Scenario 2 comparing triple combination with two reference drugs?!

Best regards
Beholder

Complete thread:

UA Flag
Activity
 Admin contact
22,478 posts in 4,708 threads, 1,604 registered users;
15 visitors (0 registered, 15 guests [including 11 identified bots]).
Forum time: 18:30 CET (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5